Cart
sales@molnova.com
ML-211
CAS No. 2205032-89-7
ML-211( —— )
Catalog No. M23993 CAS No. 2205032-89-7
ML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 231 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 620 | In Stock |
|
| 50MG | 852 | In Stock |
|
| 100MG | 1144 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML-211
-
NoteResearch use only, not for human use.
-
Brief DescriptionML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
-
DescriptionML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLYPLA1|LYPLA2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2205032-89-7
-
Formula Weight418.5
-
Molecular FormulaC25H30N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC(C)(C)C1CCN(CC1)C(=O)N2N=CC(=N2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Adibekian A , Martin B R , Chang J W , et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2)[J]. National Center for Biotechnology Information (US), 2010.
molnova catalog
related products
-
BAY-091
BAY-091 is a novel, potent, and highly selective inhibitor of PIP4K2A kinase.
-
(2R,3S,11bS)-Dihydro...
(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.
-
Kushenol I
Kushenol I is a GABAA receptor modulator, it exhibits inhibitory activity against Sodium-dependent glucose cotransporter 2(SGLT2).
